Literature DB >> 20439324

Membranoproliferative glomerulonephritis in the setting of multicentric angiofollicular lymph node hyperplasia (Castleman's disease) complicated by Evan's syndrome.

Hariklia Gakiopoulou1, Penelope Korkolopoulou, Helen Paraskevakou, Smaragdi Marinaki, Michael Voulgarelis, Anastasios Stofas, Maria Lelouda, Andreas C Lazaris, John Boletis, Efstratios Patsouris.   

Abstract

Systemic Castleman's disease is a lymphoproliferative disorder with various clinical presentations and incompletely understood aetiology. The authors report on a rare case of the plasma cell variant of Castleman's disease associated with autoimmune haemolytic anaemia and autoimmune thrombocytopenia (Evan's syndrome) and complicated by mixed nephrotic-nephritic syndrome and acute renal failure due to an underlying glomerulopathy with microscopic and immunofluorescence findings suggestive of membranoproliferative glomerulonephritis (MPGN) type I. Immunocomplexed glomerulonephritis is rare in Castleman's disease, while, to the best of our knowledge, constellation of all these autoimmune phenomena is reported for the first time suggesting that apart from the putative role of VEGF and IL-6 in the pathogenesis of the disease, a more generalised immunological disturbance occurs, probably through autoantibodies induced by active polyclonal B cells raised from Castleman's disease tumour.

Entities:  

Mesh:

Year:  2010        PMID: 20439324     DOI: 10.1136/jcp.2009.071415

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  2 in total

1.  Membranoproliferative glomerulonephritis associated with autoimmune diseases.

Authors:  Ladan Zand; Fernando C Fervenza; Samih H Nasr; Sanjeev Sethi
Journal:  J Nephrol       Date:  2014-02-06       Impact factor: 3.902

2.  Successful treatment of TAFRO syndrome, a variant type of multicentric Castleman disease with thrombotic microangiopathy, with anti-IL-6 receptor antibody and steroids.

Authors:  Shiho Fujiwara; Hiromi Mochinaga; Hirotomo Nakata; Koichi Ohshima; Masanori Matsumoto; Mitsuhiro Uchiba; Yoshiki Mikami; Hiroyuki Hata; Yutaka Okuno; Hiroaki Mitsuya; Kisato Nosaka
Journal:  Int J Hematol       Date:  2016-03-15       Impact factor: 2.490

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.